Short Interest in Catalent, Inc. (NYSE:CTLT) Rises By 7.3%

Catalent, Inc. (NYSE:CTLT) was the target of a large growth in short interest during the month of November. As of November 15th, there was short interest totalling 9,060,000 shares, a growth of 7.3% from the October 31st total of 8,440,000 shares. Based on an average daily trading volume, of 1,760,000 shares, the days-to-cover ratio is presently 5.1 days.

Insider Activity at Catalent

In related news, Director Michelle R. Ryan sold 2,800 shares of the business’s stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $59.70, for a total transaction of $167,160.00. Following the transaction, the director now directly owns 10,835 shares in the company, valued at $646,849.50. The trade was a 20.54 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider David Mcerlane sold 1,994 shares of the stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $59.97, for a total transaction of $119,580.18. Following the completion of the transaction, the insider now owns 36,304 shares of the company’s stock, valued at approximately $2,177,150.88. This represents a 5.21 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 5,114 shares of company stock worth $305,931. 0.31% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Brooklyn Investment Group acquired a new position in Catalent in the third quarter valued at about $31,000. Thurston Springer Miller Herd & Titak Inc. acquired a new stake in shares of Catalent in the 2nd quarter valued at approximately $42,000. Sentry Investment Management LLC bought a new position in Catalent during the 3rd quarter worth approximately $53,000. Longfellow Investment Management Co. LLC grew its holdings in Catalent by 45.7% during the second quarter. Longfellow Investment Management Co. LLC now owns 972 shares of the company’s stock valued at $55,000 after purchasing an additional 305 shares during the period. Finally, GAMMA Investing LLC raised its holdings in Catalent by 25.9% in the second quarter. GAMMA Investing LLC now owns 1,032 shares of the company’s stock worth $58,000 after purchasing an additional 212 shares during the period.

Analyst Ratings Changes

Several analysts recently commented on the company. William Blair reaffirmed a “market perform” rating on shares of Catalent in a research note on Tuesday, September 3rd. StockNews.com upgraded shares of Catalent from a “sell” rating to a “hold” rating in a research report on Monday. Baird R W cut shares of Catalent from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. Finally, Robert W. Baird reaffirmed a “neutral” rating and set a $63.50 price objective on shares of Catalent in a report on Tuesday, September 24th. Eight research analysts have rated the stock with a hold rating, Based on data from MarketBeat, Catalent has an average rating of “Hold” and an average target price of $63.40.

Catalent Stock Performance

CTLT stock opened at $61.72 on Wednesday. The stock has a market capitalization of $11.20 billion, a PE ratio of -27.31, a price-to-earnings-growth ratio of 2.44 and a beta of 1.15. The company has a debt-to-equity ratio of 1.38, a current ratio of 2.51 and a quick ratio of 1.96. The company has a 50 day moving average price of $59.96 and a 200 day moving average price of $58.60. Catalent has a fifty-two week low of $36.74 and a fifty-two week high of $62.08.

Catalent (NYSE:CTLT) last released its earnings results on Tuesday, November 5th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.18). The firm had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.06 billion. Catalent had a negative return on equity of 0.66% and a negative net margin of 9.28%. The company’s revenue was up 4.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.10) EPS. Analysts forecast that Catalent will post 0.84 EPS for the current year.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.